bioAffinity Technologies, Inc. 8-K

What Happened
bioAffinity Technologies, Inc. (BIAF) filed an 8-K dated April 7, 2026, announcing that its CyPath® Lung test will be featured at the invitation-only “Advances in Early Lung Cancer Detection” symposium hosted by the Cleveland Clinic in Cleveland, Ohio on April 16, 2026. The company attached a press release as Exhibit 99.1 to the filing.

Key Details

• Filing date: April 7, 2026 (Form 8-K, Item 8.01 Other Events).
• Event date: April 16, 2026 — invitation-only symposium titled “Advances in Early Lung Cancer Detection.”
• Location: Cleveland Clinic, Cleveland, Ohio.
• Press release announcing the appearance is included as Exhibit 99.1 in the 8-K.

Why It Matters
This is a non-financial disclosure that notifies investors of increased scientific visibility and engagement for bioAffinity’s CyPath Lung test at a high-profile clinical symposium. The filing does not report financial results, operational changes, or material agreements; it documents a public relations and scientific outreach event that investors may view as part of the company’s commercialization and clinical engagement activities.